Clinical trials: Substance-Related Disorder
Social Anxiety Disorder
CHI-902 for Treatment of Social Anxiety Disorder
No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy…
- Trial name
- NCT04086342
- Testing
- CHI-902
- Where
- 2 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation
Opioid Use Disorder
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
- Trial name
- NCT05924945
- Testing
- Bridge™ active device
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masimo Corporation
Substance Use Disorders
Automated Assessment Using Facial Coding
Transition-age youth (TAY) from ages 18-26 are vulnerable to substance substance use disorder (SUD). This developmental period, termed "emerging adulthood" includes leaving home, entering college or working for the first time…
- Trial name
- R44DA042640 (NCT03551886)
- Testing
- Advanced Emotion App, Basic Emotion App
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Treatment Innovations
Substance Abuse Disorder
Examining Clinical Research Participation for Substance Abuse Disorder Patient
Clinical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it…
- Trial name
- NCT05881369
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Constipation, Signs and Symptoms, Digestive
Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients
To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC) or at risk of OIC.
- Trial name
- NCT02099591
- Testing
- Naloxegol
- Where
- 16 sites in Denmark, Israel and 3 more
- Volunteers
- 61 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Neonatal Abstinence Syndrome
Donor Human Milk in Neonatal Abstinence Syndrome
This study is designed to develop pilot data on the acceptability and benefit of donor human milk for infants undergoing pharmacologic treatment for NAS.
- Trial name
- DHM&NAS (NCT02182973)
- Testing
- donor human milk
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Neolac Inc dba Medolac Laboratories
Diabetic Peripheral Neuropathic Pain
A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
The primary purpose of this study is to evaluate the safety and efficacy of medical cannabis aerosol containing 0.25, 0.50, 1.0 milligrams (mg) delta (Δ) 9-tetrahydrocannabinol (THC) inhaled three times a day (TID) compared to…
- Trial name
- NCT06490445
- Testing
- Medical Cannabis
- Where
- 38 sites in Australia, Czechia and 3 more
- Volunteers
- 122 people
- Sponsor
- Syqe Medical
Opioid-use Disorder
Single Ascending Dose Study of ALA-1000
An open-label study designed to evaluate the safety, tolerability, and pharmacokinetics of ALA-1000 in opioid-dependent subjects.
- Trial name
- NCT04122755
- Testing
- ALA-1000, buprenorphine sublingual film
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Alar Pharmaceuticals Inc.
Substance Abuse
A Clinical Decision Support Tool for Electronic Health Records
For behavioral health clinicians who are interested in getting tailored treatment and level of care recommendations, "BH-CDS" is a desktop/tablet web-based application that provides clinicians with data and a rationale for better…
- Trial name
- BHCDS (NCT02697643)
- Testing
- BHCDS-based recommendations, Non-tailored recommendations
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Inflexxion, Inc.
Alcoholic Liver Cirrhosis
Long-Term Follow-up of Patients With Alcoholic Liver Cirrhosis Treated With Cellgram-LC
The goal of this observational study is to learn about the long-term safety of Cellgram-LC in patients with alcoholic liver cirrhosis who previously received Cellgram-LC in the PMC-P-07 study.
- Trial name
- NCT05093881
- Where
- 14 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Pharmicell Co., Ltd.
Lysosomal Acid Lipase Deficiency
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.
- Trial name
- NCT02193867
- Testing
- Sebelipase Alfa
- Where
- 5 sites in United States, Finland and 2 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Healthy, Cannabis
A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population
The objective of this study is to investigate the bioavailability of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) in an emulsion product against a comparator product.
- Trial name
- NCT04601207
- Testing
- Cannabis Preparation
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- New Age Ventures LLC
Alcohol Dependence
ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)
This was a Phase 3 multicenter extension of Alkermes' Study ALK21-003 (NCT01218958 [the base study]) that evaluated the safety of Medisorb® naltrexone (VIVITROL®) administered every 4 weeks for 48 weeks (13 injections) in…
- Trial name
- NCT01218971
- Testing
- Medisorb naltrexone 190 mg, Medisorb naltrexone 380 mg
- Volunteers
- 332 people
- Sponsor
- Alkermes, Inc.
Nicotine Dependence, Other Tobacco Product, Tobacco Use
Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers
The JUUL 5% Electronic Nicotine Delivery System (ENDS) is being studied as an alternative to combustible cigarette use. This study aims to find out how much nicotine is in the blood and urine of healthy adult subjects after using…
- Conditions
- Nicotine Dependence, Other Tobacco Product, Tobacco Use, Smoking, Tobacco
- Trial name
- Diamond (NCT03463837)
- Testing
- Treatment with JUUL 5%, Virginia Tobacco, Treatment with JUUL 5%, Cool Mint, ENDS, Treatment with JUUL 5%, Mango, ENDS
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Tobacco Dependence
Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products
Multiple-dose nicotine pharmacokinetics with three oral nicotine replacement products. A study in healthy smokers.
- Trial name
- NCT01321931
- Testing
- Nicotine
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- McNeil AB
Alcohol Use Disorder, Alcohol Abuse
tAN for Substance Use Disorder
The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity (RSFC) between OFC and striatum in patients with alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse, Substance Use Disorders, Substance Use Disorders Alcohol Use Withdrawal State
- Trial name
- NCT07281261
- Testing
- Sparrow Ascent
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Spark Biomedical, Inc.
Opioid Induced Constipation
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.
- Trial name
- NCT03060512
- Testing
- Polyethylene Glycol 3350, Movantik
- Where
- 53 sites in United States
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Substance Abuse
Efficacy of Centervention-ATOD: An Implementation Tool for Dissemination of Evidence-based Programs for Substance Abuse
The pilot test of Centervention-ATOD, a customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings, will evaluate whether the…
- Trial name
- CV-ATOD (NCT03084406)
- Testing
- Centervention-ATOD (CV-ATOD)
- Where
- United States
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- 3-C Institute for Social Development
Cigarette Smoking
Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users
To better understand the PK and associated pharmacodynamic (PD) responses produced by the Research ENDS S-TA-U001 product, this study will compare the Research ENDS S-TA-U001 to The subject's own brand combustion (non-menthol)…
- Trial name
- NCT02792426
- Testing
- Research ENDS S-TA-U001, Nicorette Inhalator
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NJOY, Inc.
Healthy Smokers
Nicotine Patch - Multidose Bioequivalence Study
The purpose of this study is to compare the relative bioavailability of nicotine following repeated applications of a new transdermal formulation to that of a reference formulation. Up to day 7
- Trial name
- NCT01658215
- Testing
- V0116 transdermal patch (Test treatment ), Nicotine transdermal patch (Reference treatment )
- Where
- France
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament